Oral idasanutlin in patients with polycythemia vera

John Mascarenhas, Min Lu, Heidi Kosiorek, Elizabeth Virtgaym, Lijuan Xia, Lonette Sandy, Ruben Mesa, Bruce Petersen, Noushin Farnoud, Vesna Najfeld, Raajit Rampal, Amylou Dueck, Ronald Hoffman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A limited number of drugs are available to treat patients with polycythemia vera (PV) and essential thrombocythemia (ET). We attempted to identify alternative agents that may target abnormalities within malignant hematopoietic stem (HSCs) and progenitor cells (HPCs). Previously, MDM2 protein levels were shown to be upregulated in PV/ET CD341 cells, and exposure to a nutlin, an MDM2 antagonist, induced activation of the TP53 pathway and selective depletion of PV HPCs/HSCs. This anticlonal activity was mediated by upregulation of p53 and potentiated by the addition of interferon-a2a (IFN-a2a). Therefore, we performed an investigator-initiated phase 1 trial of the oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV/ET for whom at least 1 prior therapy had failed. Patients not attaining at least a partial response by European LeukemiaNet criteria after 6 cycles were then allowed to receive combination therapy with low-dose pegylated IFN-a2a. Thirteen patients with JAK2 V617F1 PV/ET were enrolled, and 12 (PV, n 5 11; ET, n 5 1) were treated with idasanutlin at 100 and 150 mg daily, respectively, for 5 consecutive days of a 28-day cycle. Idasanutlin was well tolerated; no dose-limiting toxicity was observed, but low-grade gastrointestinal toxicity was common. Overall response rate after 6 cycles was 58% (7 of 12) with idasanutlin monotherapy and 50% (2 of 4) with combination therapy. Median duration of response was 16.8 months (range, 3.5-26.7). Hematologic, symptomatic, pathologic, and molecular responses were observed. These data indicate that idasanutlin is a promising novel agent for PV; it is currently being evaluated in a global phase 2 trial. This trial was registered at www.clinicaltrials.gov as #NCT02407080.

Original languageEnglish (US)
Pages (from-to)525-533
Number of pages9
JournalBlood
Volume134
Issue number6
DOIs
StatePublished - Aug 8 2019

Fingerprint

Polycythemia Vera
Essential Thrombocythemia
Interferons
Toxicity
Chemical activation
Hematopoietic Stem Cells
Pharmaceutical Preparations
Proteins
Up-Regulation
Stem Cells
Therapeutics
Research Personnel
RG7388

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Mascarenhas, J., Lu, M., Kosiorek, H., Virtgaym, E., Xia, L., Sandy, L., ... Hoffman, R. (2019). Oral idasanutlin in patients with polycythemia vera. Blood, 134(6), 525-533. https://doi.org/10.1182/blood.2018893545

Oral idasanutlin in patients with polycythemia vera. / Mascarenhas, John; Lu, Min; Kosiorek, Heidi; Virtgaym, Elizabeth; Xia, Lijuan; Sandy, Lonette; Mesa, Ruben; Petersen, Bruce; Farnoud, Noushin; Najfeld, Vesna; Rampal, Raajit; Dueck, Amylou; Hoffman, Ronald.

In: Blood, Vol. 134, No. 6, 08.08.2019, p. 525-533.

Research output: Contribution to journalArticle

Mascarenhas, J, Lu, M, Kosiorek, H, Virtgaym, E, Xia, L, Sandy, L, Mesa, R, Petersen, B, Farnoud, N, Najfeld, V, Rampal, R, Dueck, A & Hoffman, R 2019, 'Oral idasanutlin in patients with polycythemia vera', Blood, vol. 134, no. 6, pp. 525-533. https://doi.org/10.1182/blood.2018893545
Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L et al. Oral idasanutlin in patients with polycythemia vera. Blood. 2019 Aug 8;134(6):525-533. https://doi.org/10.1182/blood.2018893545
Mascarenhas, John ; Lu, Min ; Kosiorek, Heidi ; Virtgaym, Elizabeth ; Xia, Lijuan ; Sandy, Lonette ; Mesa, Ruben ; Petersen, Bruce ; Farnoud, Noushin ; Najfeld, Vesna ; Rampal, Raajit ; Dueck, Amylou ; Hoffman, Ronald. / Oral idasanutlin in patients with polycythemia vera. In: Blood. 2019 ; Vol. 134, No. 6. pp. 525-533.
@article{7b633e636c2248fdbbd5ff72e4e552eb,
title = "Oral idasanutlin in patients with polycythemia vera",
abstract = "A limited number of drugs are available to treat patients with polycythemia vera (PV) and essential thrombocythemia (ET). We attempted to identify alternative agents that may target abnormalities within malignant hematopoietic stem (HSCs) and progenitor cells (HPCs). Previously, MDM2 protein levels were shown to be upregulated in PV/ET CD341 cells, and exposure to a nutlin, an MDM2 antagonist, induced activation of the TP53 pathway and selective depletion of PV HPCs/HSCs. This anticlonal activity was mediated by upregulation of p53 and potentiated by the addition of interferon-a2a (IFN-a2a). Therefore, we performed an investigator-initiated phase 1 trial of the oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV/ET for whom at least 1 prior therapy had failed. Patients not attaining at least a partial response by European LeukemiaNet criteria after 6 cycles were then allowed to receive combination therapy with low-dose pegylated IFN-a2a. Thirteen patients with JAK2 V617F1 PV/ET were enrolled, and 12 (PV, n 5 11; ET, n 5 1) were treated with idasanutlin at 100 and 150 mg daily, respectively, for 5 consecutive days of a 28-day cycle. Idasanutlin was well tolerated; no dose-limiting toxicity was observed, but low-grade gastrointestinal toxicity was common. Overall response rate after 6 cycles was 58{\%} (7 of 12) with idasanutlin monotherapy and 50{\%} (2 of 4) with combination therapy. Median duration of response was 16.8 months (range, 3.5-26.7). Hematologic, symptomatic, pathologic, and molecular responses were observed. These data indicate that idasanutlin is a promising novel agent for PV; it is currently being evaluated in a global phase 2 trial. This trial was registered at www.clinicaltrials.gov as #NCT02407080.",
author = "John Mascarenhas and Min Lu and Heidi Kosiorek and Elizabeth Virtgaym and Lijuan Xia and Lonette Sandy and Ruben Mesa and Bruce Petersen and Noushin Farnoud and Vesna Najfeld and Raajit Rampal and Amylou Dueck and Ronald Hoffman",
year = "2019",
month = "8",
day = "8",
doi = "10.1182/blood.2018893545",
language = "English (US)",
volume = "134",
pages = "525--533",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Oral idasanutlin in patients with polycythemia vera

AU - Mascarenhas, John

AU - Lu, Min

AU - Kosiorek, Heidi

AU - Virtgaym, Elizabeth

AU - Xia, Lijuan

AU - Sandy, Lonette

AU - Mesa, Ruben

AU - Petersen, Bruce

AU - Farnoud, Noushin

AU - Najfeld, Vesna

AU - Rampal, Raajit

AU - Dueck, Amylou

AU - Hoffman, Ronald

PY - 2019/8/8

Y1 - 2019/8/8

N2 - A limited number of drugs are available to treat patients with polycythemia vera (PV) and essential thrombocythemia (ET). We attempted to identify alternative agents that may target abnormalities within malignant hematopoietic stem (HSCs) and progenitor cells (HPCs). Previously, MDM2 protein levels were shown to be upregulated in PV/ET CD341 cells, and exposure to a nutlin, an MDM2 antagonist, induced activation of the TP53 pathway and selective depletion of PV HPCs/HSCs. This anticlonal activity was mediated by upregulation of p53 and potentiated by the addition of interferon-a2a (IFN-a2a). Therefore, we performed an investigator-initiated phase 1 trial of the oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV/ET for whom at least 1 prior therapy had failed. Patients not attaining at least a partial response by European LeukemiaNet criteria after 6 cycles were then allowed to receive combination therapy with low-dose pegylated IFN-a2a. Thirteen patients with JAK2 V617F1 PV/ET were enrolled, and 12 (PV, n 5 11; ET, n 5 1) were treated with idasanutlin at 100 and 150 mg daily, respectively, for 5 consecutive days of a 28-day cycle. Idasanutlin was well tolerated; no dose-limiting toxicity was observed, but low-grade gastrointestinal toxicity was common. Overall response rate after 6 cycles was 58% (7 of 12) with idasanutlin monotherapy and 50% (2 of 4) with combination therapy. Median duration of response was 16.8 months (range, 3.5-26.7). Hematologic, symptomatic, pathologic, and molecular responses were observed. These data indicate that idasanutlin is a promising novel agent for PV; it is currently being evaluated in a global phase 2 trial. This trial was registered at www.clinicaltrials.gov as #NCT02407080.

AB - A limited number of drugs are available to treat patients with polycythemia vera (PV) and essential thrombocythemia (ET). We attempted to identify alternative agents that may target abnormalities within malignant hematopoietic stem (HSCs) and progenitor cells (HPCs). Previously, MDM2 protein levels were shown to be upregulated in PV/ET CD341 cells, and exposure to a nutlin, an MDM2 antagonist, induced activation of the TP53 pathway and selective depletion of PV HPCs/HSCs. This anticlonal activity was mediated by upregulation of p53 and potentiated by the addition of interferon-a2a (IFN-a2a). Therefore, we performed an investigator-initiated phase 1 trial of the oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV/ET for whom at least 1 prior therapy had failed. Patients not attaining at least a partial response by European LeukemiaNet criteria after 6 cycles were then allowed to receive combination therapy with low-dose pegylated IFN-a2a. Thirteen patients with JAK2 V617F1 PV/ET were enrolled, and 12 (PV, n 5 11; ET, n 5 1) were treated with idasanutlin at 100 and 150 mg daily, respectively, for 5 consecutive days of a 28-day cycle. Idasanutlin was well tolerated; no dose-limiting toxicity was observed, but low-grade gastrointestinal toxicity was common. Overall response rate after 6 cycles was 58% (7 of 12) with idasanutlin monotherapy and 50% (2 of 4) with combination therapy. Median duration of response was 16.8 months (range, 3.5-26.7). Hematologic, symptomatic, pathologic, and molecular responses were observed. These data indicate that idasanutlin is a promising novel agent for PV; it is currently being evaluated in a global phase 2 trial. This trial was registered at www.clinicaltrials.gov as #NCT02407080.

UR - http://www.scopus.com/inward/record.url?scp=85070741891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070741891&partnerID=8YFLogxK

U2 - 10.1182/blood.2018893545

DO - 10.1182/blood.2018893545

M3 - Article

VL - 134

SP - 525

EP - 533

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -